Pharvaris Announces Statistically Significant And Clinically Meaningful Topline Results From Its CHAPTER-3 Pivotal Phase 3 Study Evaluating Deucrictibant Extended-Release Tablet For Prevention Of HAE Attacks; Primary Endpoint And All Secondary Efficacy Endpoints Were Met With Statistical Significance

Benzinga Newsdesk www.benzinga.com Positive 66.9%

Neg 0% Neu 0% Pos 66.9%

Primary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in the first and only prophylaxis Phase 3 study in all three types of HAE
87% attack rate reduction versus placebo observed in people with HAE Type 1 or Type 2
All secondary efficacy endpoints met with statistical significance
Well-tolerated safety profile of deucrictibant XR demonstrated
Conference call and webcast today at 8:00 a.m. EDT

Comments

No comments yet. Be the first!